Share Price and Basic Stock Data
Last Updated: January 23, 2026, 6:15 pm
| PEG Ratio | -4.31 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Dev Labtech Venture Ltd operates in a niche segment with a market capitalization of ₹116 Cr, reflecting a price of ₹98.1 per share. The company has shown a notable upward trajectory in its revenue, with sales reported at ₹30.34 Cr for the year ending March 2023, which increased to ₹52.41 Cr for the year ending March 2025. This represents a growth of approximately 73.7% over the two-year period. Quarterly sales figures indicate consistent performance, with ₹20.68 Cr in March 2023 and ₹22.30 Cr in March 2024. However, in the subsequent quarters, there was a drop to ₹19.51 Cr in September 2024, which may raise concerns about seasonality or demand fluctuations. The trailing twelve months (TTM) revenue stood at ₹82.14 Cr, showcasing the company’s robust operational capabilities in generating consistent sales. The reported operating profit margin (OPM) fluctuated between 1.97% and 10.56% across the quarters, indicating variability in cost management and pricing strategy.
Profitability and Efficiency Metrics
Profitability metrics for Dev Labtech Venture Ltd reveal a mixed performance. The net profit for the year ending March 2025 was ₹1.29 Cr, with a net profit margin of 2.46%, indicating relatively low profitability compared to industry norms. The company’s return on equity (ROE) stood at 3.14%, while return on capital employed (ROCE) was reported at 4.63%, both of which are lower than typical sector averages, suggesting inefficiencies in capital utilization. The interest coverage ratio (ICR) reported at 25.49x highlights the company’s strong ability to cover its interest obligations, indicating financial stability. The cash conversion cycle (CCC) has significantly increased to 313.45 days, which raises concerns regarding the efficiency of the company’s working capital management. Overall, while the company has demonstrated the ability to generate profits, the low margins and extended cash conversion cycle may hinder its growth potential.
Balance Sheet Strength and Financial Ratios
Dev Labtech’s balance sheet reflects a sound financial structure with total assets reported at ₹49.12 Cr and total liabilities at ₹49.12 Cr as of September 2025. The company’s reserves have increased to ₹32.25 Cr, indicating a strong retained earnings position that can support future growth. The borrowings stood at a mere ₹1.07 Cr, resulting in a low debt-to-equity ratio of 0.02, showcasing the company’s conservative financing strategy. The current ratio of 29.54x and quick ratio of 5.02x indicate a strong liquidity position, well above typical benchmarks, suggesting that the company can meet its short-term obligations comfortably. However, the company’s price-to-book value (P/BV) ratio of 1.63x suggests that the market has a positive outlook on its asset base, albeit with a premium that may not be justified given the low ROE and ROCE. The financial ratios indicate a stable yet cautious approach to capital management.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Dev Labtech Venture Ltd reflects a significant concentration of ownership among promoters, who held 56.69% as of September 2025. This level of promoter holding can instill confidence among investors regarding the commitment of management to the company’s long-term success. The public holding stood at 43.31%, indicating a relatively high level of retail investor participation. The number of shareholders increased to 955, suggesting growing interest in the company, which is a positive indicator of investor confidence. However, the volatility in promoter holdings, which declined from 68.01% in March 2023 to 54.58% in September 2024, may raise concerns about potential dilution or shifts in management strategy. The absence of Foreign Institutional Investors (FIIs) and Domestic Institutional Investors (DIIs) participation indicates a lack of institutional backing, which could be a risk factor in terms of stock liquidity and overall market perception.
Outlook, Risks, and Final Insight
Looking ahead, Dev Labtech Venture Ltd faces both opportunities and challenges. The substantial growth in revenue indicates potential for scaling operations, but low profitability metrics pose a risk to sustainable growth. The company’s high cash conversion cycle raises operational efficiency concerns that need addressing to improve working capital management. Furthermore, the lack of institutional investment could limit the stock’s market appeal, potentially affecting liquidity. On the positive side, the strong liquidity position and low debt levels provide a buffer against market volatility and financial distress. If the company can streamline operations to improve margins while maintaining revenue growth, it may enhance shareholder value. However, any significant shifts in market dynamics or operational inefficiencies could pose risks to its financial stability and growth trajectory.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Gujarat Metallic Coal & Coke Ltd | 5.94 Cr. | 30.0 | / | 77.6 | 0.00 % | 0.37 % | 2.00 % | 100 | |
| Gensol Engineering Ltd | 88.5 Cr. | 23.2 | 776/20.5 | 0.87 | 155 | 0.00 % | 14.3 % | 22.4 % | 10.0 |
| Fusion Micro Finance Ltd | 2,819 Cr. | 175 | 212/124 | 118 | 0.00 % | 2.96 % | 54.5 % | 10.0 | |
| Five X Tradecom Ltd | 0.99 Cr. | 0.48 | / | 9.35 | 0.00 % | 0.00 % | 0.00 % | 10.0 | |
| East West Holdings Ltd | 36.9 Cr. | 2.89 | 8.19/2.70 | 4.93 | 0.00 % | 6.98 % | 0.86 % | 2.00 | |
| Industry Average | 6,325.83 Cr | 198.39 | 261.23 | 219.28 | 0.27% | 11.73% | 22.92% | 9.00 |
Quarterly Result
| Metric | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|
| Sales | 19.43 | 9.66 | 20.68 | 20.92 | 22.30 | 19.51 | 32.90 | 49.24 |
| Expenses | 18.99 | 8.64 | 19.80 | 18.82 | 21.53 | 18.30 | 31.03 | 48.27 |
| Operating Profit | 0.44 | 1.02 | 0.88 | 2.10 | 0.77 | 1.21 | 1.87 | 0.97 |
| OPM % | 2.26% | 10.56% | 4.26% | 10.04% | 3.45% | 6.20% | 5.68% | 1.97% |
| Other Income | 0.11 | 0.16 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.06 | 0.05 | 0.05 | 0.07 | 0.05 | 0.05 | 0.07 | 0.04 |
| Depreciation | 0.04 | 0.27 | 0.29 | 0.46 | 0.47 | 0.50 | 0.61 | 0.56 |
| Profit before tax | 0.45 | 0.86 | 0.54 | 1.58 | 0.25 | 0.66 | 1.19 | 0.37 |
| Tax % | 15.56% | 34.88% | 18.52% | 17.09% | 88.00% | 25.76% | 31.93% | 5.41% |
| Net Profit | 0.37 | 0.57 | 0.45 | 1.31 | 0.03 | 0.48 | 0.81 | 0.34 |
| EPS in Rs | 2.94 | 1.17 | 0.54 | 1.58 | 0.04 | 0.46 | 0.72 | 0.29 |
Last Updated: December 27, 2025, 7:31 am
Below is a detailed analysis of the quarterly data for Dev Labtech Venture Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 49.24 Cr.. The value appears strong and on an upward trend. It has increased from 32.90 Cr. (Mar 2025) to 49.24 Cr., marking an increase of 16.34 Cr..
- For Expenses, as of Sep 2025, the value is 48.27 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 31.03 Cr. (Mar 2025) to 48.27 Cr., marking an increase of 17.24 Cr..
- For Operating Profit, as of Sep 2025, the value is 0.97 Cr.. The value appears to be declining and may need further review. It has decreased from 1.87 Cr. (Mar 2025) to 0.97 Cr., marking a decrease of 0.90 Cr..
- For OPM %, as of Sep 2025, the value is 1.97%. The value appears to be declining and may need further review. It has decreased from 5.68% (Mar 2025) to 1.97%, marking a decrease of 3.71%.
- For Other Income, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Interest, as of Sep 2025, the value is 0.04 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.07 Cr. (Mar 2025) to 0.04 Cr., marking a decrease of 0.03 Cr..
- For Depreciation, as of Sep 2025, the value is 0.56 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.61 Cr. (Mar 2025) to 0.56 Cr., marking a decrease of 0.05 Cr..
- For Profit before tax, as of Sep 2025, the value is 0.37 Cr.. The value appears to be declining and may need further review. It has decreased from 1.19 Cr. (Mar 2025) to 0.37 Cr., marking a decrease of 0.82 Cr..
- For Tax %, as of Sep 2025, the value is 5.41%. The value appears to be improving (decreasing) as expected. It has decreased from 31.93% (Mar 2025) to 5.41%, marking a decrease of 26.52%.
- For Net Profit, as of Sep 2025, the value is 0.34 Cr.. The value appears to be declining and may need further review. It has decreased from 0.81 Cr. (Mar 2025) to 0.34 Cr., marking a decrease of 0.47 Cr..
- For EPS in Rs, as of Sep 2025, the value is 0.29. The value appears to be declining and may need further review. It has decreased from 0.72 (Mar 2025) to 0.29, marking a decrease of 0.43.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:52 am
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 11.79 | 12.24 | 26.98 | 30.34 | 43.22 | 52.41 | 82.14 |
| Expenses | 11.41 | 11.96 | 26.28 | 28.43 | 40.35 | 49.33 | 79.30 |
| Operating Profit | 0.38 | 0.28 | 0.70 | 1.91 | 2.87 | 3.08 | 2.84 |
| OPM % | 3.22% | 2.29% | 2.59% | 6.30% | 6.64% | 5.88% | 3.46% |
| Other Income | 0.00 | 0.04 | 0.12 | 0.16 | 0.01 | 0.00 | 0.00 |
| Interest | 0.18 | 0.16 | 0.14 | 0.10 | 0.12 | 0.12 | 0.11 |
| Depreciation | 0.15 | 0.11 | 0.09 | 0.55 | 0.93 | 1.11 | 1.17 |
| Profit before tax | 0.05 | 0.05 | 0.59 | 1.42 | 1.83 | 1.85 | 1.56 |
| Tax % | 100.00% | 40.00% | 16.95% | 27.46% | 26.78% | 29.73% | |
| Net Profit | 0.00 | 0.04 | 0.49 | 1.02 | 1.34 | 1.29 | 1.15 |
| EPS in Rs | 0.00 | 1.91 | 3.90 | 1.23 | 1.62 | 1.14 | 1.01 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|
| YoY Net Profit Growth (%) | 1125.00% | 108.16% | 31.37% | -3.73% |
| Change in YoY Net Profit Growth (%) | 0.00% | -1016.84% | -76.79% | -35.10% |
Dev Labtech Venture Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 4 years from 2021-2022 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 35% |
| 3 Years: | 25% |
| TTM: | 21% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 48% |
| TTM: | -4% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -26% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 6% |
| 3 Years: | 5% |
| Last Year: | 4% |
Last Updated: September 5, 2025, 3:11 pm
Balance Sheet
Last Updated: December 4, 2025, 2:44 am
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.21 | 0.21 | 1.26 | 8.27 | 8.27 | 11.30 | 11.86 |
| Reserves | 1.24 | 1.28 | 0.77 | 10.61 | 17.51 | 29.87 | 32.25 |
| Borrowings | 1.54 | 1.78 | 1.23 | 1.13 | 1.10 | 1.07 | 1.07 |
| Other Liabilities | 4.13 | 3.87 | 5.68 | 3.72 | 1.79 | 1.53 | 3.94 |
| Total Liabilities | 7.12 | 7.14 | 8.94 | 23.73 | 28.67 | 43.77 | 49.12 |
| Fixed Assets | 0.81 | 0.71 | 0.37 | 4.15 | 5.01 | 4.89 | 4.36 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Other Assets | 6.31 | 6.43 | 8.57 | 19.58 | 23.66 | 38.88 | 44.75 |
| Total Assets | 7.12 | 7.14 | 8.94 | 23.73 | 28.67 | 43.77 | 49.12 |
Below is a detailed analysis of the balance sheet data for Dev Labtech Venture Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 11.86 Cr.. The value appears strong and on an upward trend. It has increased from 11.30 Cr. (Mar 2025) to 11.86 Cr., marking an increase of 0.56 Cr..
- For Reserves, as of Sep 2025, the value is 32.25 Cr.. The value appears strong and on an upward trend. It has increased from 29.87 Cr. (Mar 2025) to 32.25 Cr., marking an increase of 2.38 Cr..
- For Borrowings, as of Sep 2025, the value is 1.07 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2025) which recorded 1.07 Cr..
- For Other Liabilities, as of Sep 2025, the value is 3.94 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.53 Cr. (Mar 2025) to 3.94 Cr., marking an increase of 2.41 Cr..
- For Total Liabilities, as of Sep 2025, the value is 49.12 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 43.77 Cr. (Mar 2025) to 49.12 Cr., marking an increase of 5.35 Cr..
- For Fixed Assets, as of Sep 2025, the value is 4.36 Cr.. The value appears to be declining and may need further review. It has decreased from 4.89 Cr. (Mar 2025) to 4.36 Cr., marking a decrease of 0.53 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.01 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2025) to 0.01 Cr., marking an increase of 0.01 Cr..
- For Other Assets, as of Sep 2025, the value is 44.75 Cr.. The value appears strong and on an upward trend. It has increased from 38.88 Cr. (Mar 2025) to 44.75 Cr., marking an increase of 5.87 Cr..
- For Total Assets, as of Sep 2025, the value is 49.12 Cr.. The value appears strong and on an upward trend. It has increased from 43.77 Cr. (Mar 2025) to 49.12 Cr., marking an increase of 5.35 Cr..
Notably, the Reserves (32.25 Cr.) exceed the Borrowings (1.07 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Free Cash Flow | -1.16 | -1.50 | -0.53 | 0.78 | 1.77 | 2.01 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Debtor Days | 70.28 | 89.16 | 55.20 | 56.54 | 16.13 | 33.43 |
| Inventory Days | 191.01 | 123.38 | 48.27 | 122.84 | 208.18 | 285.06 |
| Days Payable | 192.65 | 160.22 | 85.88 | 33.95 | 5.37 | 5.04 |
| Cash Conversion Cycle | 68.63 | 52.32 | 17.58 | 145.43 | 218.94 | 313.45 |
| Working Capital Days | 46.44 | 56.36 | 33.28 | 119.58 | 183.94 | 261.02 |
| ROCE % | 6.71% | 18.99% | 11.69% | 8.32% | 5.70% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 1.31 | 1.62 | 0.96 | 3.47 | 1.74 |
| Diluted EPS (Rs.) | 1.09 | 1.62 | 0.96 | 3.47 | 1.74 |
| Cash EPS (Rs.) | 2.13 | 2.75 | 1.90 | 4.16 | 6.84 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 36.42 | 31.16 | 22.83 | 15.28 | 70.86 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 36.42 | 31.16 | 22.83 | 15.28 | 70.86 |
| Revenue From Operations / Share (Rs.) | 46.37 | 52.26 | 36.68 | 213.58 | 584.18 |
| PBDIT / Share (Rs.) | 2.72 | 3.48 | 2.31 | 5.42 | 15.30 |
| PBIT / Share (Rs.) | 1.74 | 2.36 | 1.64 | 4.74 | 10.20 |
| PBT / Share (Rs.) | 1.63 | 2.21 | 1.70 | 3.63 | 2.61 |
| Net Profit / Share (Rs.) | 1.14 | 1.62 | 1.23 | 3.47 | 1.74 |
| PBDIT Margin (%) | 5.86 | 6.66 | 6.29 | 2.53 | 2.61 |
| PBIT Margin (%) | 3.75 | 4.50 | 4.46 | 2.21 | 1.74 |
| PBT Margin (%) | 3.52 | 4.23 | 4.64 | 1.69 | 0.44 |
| Net Profit Margin (%) | 2.46 | 3.10 | 3.35 | 1.62 | 0.29 |
| Return on Networth / Equity (%) | 3.14 | 5.20 | 5.39 | 22.71 | 2.45 |
| Return on Capital Employeed (%) | 4.63 | 7.22 | 6.77 | 19.08 | 7.35 |
| Return On Assets (%) | 2.95 | 4.67 | 4.29 | 4.91 | 0.51 |
| Long Term Debt / Equity (X) | 0.02 | 0.04 | 0.05 | 0.59 | 0.93 |
| Total Debt / Equity (X) | 0.02 | 0.04 | 0.05 | 0.63 | 1.20 |
| Asset Turnover Ratio (%) | 1.45 | 1.65 | 1.86 | 3.35 | 1.72 |
| Current Ratio (X) | 29.54 | 14.01 | 5.24 | 1.44 | 1.45 |
| Quick Ratio (X) | 5.02 | 2.28 | 3.18 | 0.90 | 0.77 |
| Inventory Turnover Ratio (X) | 2.01 | 0.16 | 0.83 | 8.34 | 1.03 |
| Interest Coverage Ratio (X) | 25.49 | 24.43 | 18.29 | 4.89 | 2.02 |
| Interest Coverage Ratio (Post Tax) (X) | 11.72 | 12.38 | 9.23 | 3.31 | 1.23 |
| Enterprise Value (Cr.) | 68.21 | 83.64 | 37.44 | 0.00 | 0.00 |
| EV / Net Operating Revenue (X) | 1.30 | 1.94 | 1.23 | 0.00 | 0.00 |
| EV / EBITDA (X) | 22.17 | 29.04 | 19.60 | 0.00 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 1.28 | 1.91 | 1.39 | 0.00 | 0.00 |
| Price / BV (X) | 1.63 | 3.21 | 2.23 | 0.00 | 0.00 |
| Price / Net Operating Revenue (X) | 1.28 | 1.91 | 1.39 | 0.00 | 0.00 |
| EarningsYield | 0.01 | 0.01 | 0.02 | 0.00 | 0.00 |
After reviewing the key financial ratios for Dev Labtech Venture Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 1.31. This value is below the healthy minimum of 5. It has decreased from 1.62 (Mar 24) to 1.31, marking a decrease of 0.31.
- For Diluted EPS (Rs.), as of Mar 25, the value is 1.09. This value is below the healthy minimum of 5. It has decreased from 1.62 (Mar 24) to 1.09, marking a decrease of 0.53.
- For Cash EPS (Rs.), as of Mar 25, the value is 2.13. This value is below the healthy minimum of 3. It has decreased from 2.75 (Mar 24) to 2.13, marking a decrease of 0.62.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 36.42. It has increased from 31.16 (Mar 24) to 36.42, marking an increase of 5.26.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 36.42. It has increased from 31.16 (Mar 24) to 36.42, marking an increase of 5.26.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 46.37. It has decreased from 52.26 (Mar 24) to 46.37, marking a decrease of 5.89.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 2.72. This value is within the healthy range. It has decreased from 3.48 (Mar 24) to 2.72, marking a decrease of 0.76.
- For PBIT / Share (Rs.), as of Mar 25, the value is 1.74. This value is within the healthy range. It has decreased from 2.36 (Mar 24) to 1.74, marking a decrease of 0.62.
- For PBT / Share (Rs.), as of Mar 25, the value is 1.63. This value is within the healthy range. It has decreased from 2.21 (Mar 24) to 1.63, marking a decrease of 0.58.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 1.14. This value is below the healthy minimum of 2. It has decreased from 1.62 (Mar 24) to 1.14, marking a decrease of 0.48.
- For PBDIT Margin (%), as of Mar 25, the value is 5.86. This value is below the healthy minimum of 10. It has decreased from 6.66 (Mar 24) to 5.86, marking a decrease of 0.80.
- For PBIT Margin (%), as of Mar 25, the value is 3.75. This value is below the healthy minimum of 10. It has decreased from 4.50 (Mar 24) to 3.75, marking a decrease of 0.75.
- For PBT Margin (%), as of Mar 25, the value is 3.52. This value is below the healthy minimum of 10. It has decreased from 4.23 (Mar 24) to 3.52, marking a decrease of 0.71.
- For Net Profit Margin (%), as of Mar 25, the value is 2.46. This value is below the healthy minimum of 5. It has decreased from 3.10 (Mar 24) to 2.46, marking a decrease of 0.64.
- For Return on Networth / Equity (%), as of Mar 25, the value is 3.14. This value is below the healthy minimum of 15. It has decreased from 5.20 (Mar 24) to 3.14, marking a decrease of 2.06.
- For Return on Capital Employeed (%), as of Mar 25, the value is 4.63. This value is below the healthy minimum of 10. It has decreased from 7.22 (Mar 24) to 4.63, marking a decrease of 2.59.
- For Return On Assets (%), as of Mar 25, the value is 2.95. This value is below the healthy minimum of 5. It has decreased from 4.67 (Mar 24) to 2.95, marking a decrease of 1.72.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 0.2. It has decreased from 0.04 (Mar 24) to 0.02, marking a decrease of 0.02.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.02. This value is within the healthy range. It has decreased from 0.04 (Mar 24) to 0.02, marking a decrease of 0.02.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.45. It has decreased from 1.65 (Mar 24) to 1.45, marking a decrease of 0.20.
- For Current Ratio (X), as of Mar 25, the value is 29.54. This value exceeds the healthy maximum of 3. It has increased from 14.01 (Mar 24) to 29.54, marking an increase of 15.53.
- For Quick Ratio (X), as of Mar 25, the value is 5.02. This value exceeds the healthy maximum of 2. It has increased from 2.28 (Mar 24) to 5.02, marking an increase of 2.74.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 2.01. This value is below the healthy minimum of 4. It has increased from 0.16 (Mar 24) to 2.01, marking an increase of 1.85.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 25.49. This value is within the healthy range. It has increased from 24.43 (Mar 24) to 25.49, marking an increase of 1.06.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 11.72. This value is within the healthy range. It has decreased from 12.38 (Mar 24) to 11.72, marking a decrease of 0.66.
- For Enterprise Value (Cr.), as of Mar 25, the value is 68.21. It has decreased from 83.64 (Mar 24) to 68.21, marking a decrease of 15.43.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.30. This value is within the healthy range. It has decreased from 1.94 (Mar 24) to 1.30, marking a decrease of 0.64.
- For EV / EBITDA (X), as of Mar 25, the value is 22.17. This value exceeds the healthy maximum of 15. It has decreased from 29.04 (Mar 24) to 22.17, marking a decrease of 6.87.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.28. This value is within the healthy range. It has decreased from 1.91 (Mar 24) to 1.28, marking a decrease of 0.63.
- For Price / BV (X), as of Mar 25, the value is 1.63. This value is within the healthy range. It has decreased from 3.21 (Mar 24) to 1.63, marking a decrease of 1.58.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.28. This value is within the healthy range. It has decreased from 1.91 (Mar 24) to 1.28, marking a decrease of 0.63.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Dev Labtech Venture Ltd:
- Net Profit Margin: 2.46%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 4.63% (Industry Average ROCE: 11.73%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 3.14% (Industry Average ROE: 22.92%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 11.72
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 5.02
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 102 (Industry average Stock P/E: 261.23)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.02
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 2.46%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Gems, Jewellery & Precious Metals | GF/22-23, Pattani Plaza, Bhavnagar Gujarat 364002 | info@devlabtechventure.com http://www.devlabtechventure.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Jerambhai Lavjibhai Donda | Chairman & Managing Director |
| Mr. Jay Jerambhai Donda | WholeTime Director & CFO |
| Mrs. Dimple Jay Donda | Non Executive Director |
| Mr. Vivekbhai Tulsibhai Mavani | Ind. Non-Executive Director |
| Mr. Brijeshkumar Maheshbhai Pathak | Ind. Non-Executive Director |
FAQ
What is the intrinsic value of Dev Labtech Venture Ltd?
Dev Labtech Venture Ltd's intrinsic value (as of 23 January 2026) is ₹90.98 which is 8.10% lower the current market price of ₹99.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹117 Cr. market cap, FY2025-2026 high/low of ₹105/52.0, reserves of ₹32.25 Cr, and liabilities of ₹49.12 Cr.
What is the Market Cap of Dev Labtech Venture Ltd?
The Market Cap of Dev Labtech Venture Ltd is 117 Cr..
What is the current Stock Price of Dev Labtech Venture Ltd as on 23 January 2026?
The current stock price of Dev Labtech Venture Ltd as on 23 January 2026 is ₹99.0.
What is the High / Low of Dev Labtech Venture Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Dev Labtech Venture Ltd stocks is ₹105/52.0.
What is the Stock P/E of Dev Labtech Venture Ltd?
The Stock P/E of Dev Labtech Venture Ltd is 102.
What is the Book Value of Dev Labtech Venture Ltd?
The Book Value of Dev Labtech Venture Ltd is 37.2.
What is the Dividend Yield of Dev Labtech Venture Ltd?
The Dividend Yield of Dev Labtech Venture Ltd is 0.00 %.
What is the ROCE of Dev Labtech Venture Ltd?
The ROCE of Dev Labtech Venture Ltd is 5.70 %.
What is the ROE of Dev Labtech Venture Ltd?
The ROE of Dev Labtech Venture Ltd is 3.85 %.
What is the Face Value of Dev Labtech Venture Ltd?
The Face Value of Dev Labtech Venture Ltd is 10.0.